Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 274 results for obesity

  1. In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  2. Mandibular advancement splints for severe OSAHS: What is the clinical and cost effectiveness of mandibular advancement splints for managing severe OSAHS?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  3. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

  4. Mandibular advancement splints for mild symptomatic OSAHS and moderate OSAHS: In mild symptomatic OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  5. Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with placebo in people with OSAHS who are unable to tolerate CPAP?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  6. Upper airway surgery in people unable to tolerate or adhere to CPAP: What is the clinical and cost effectiveness of upper airway surgical interventions for people with OSAHS who are unable to tolerate or adhere to CPAP?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  7. What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing moderate and severe OSAHS?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  8. Treatment for people with COPD–OSAHS overlap syndrome: What is the optimal treatment for people with COPD–OSAHS overlap syndrome: non-invasive ventilation or CPAP?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  9. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

  10. Auto- versus fixed-level CPAP for OSAHS: What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

  11. PICO negative pressure wound dressings for closed surgical incisions (HTG509)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

  12. Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)

    This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.